<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_Tctpncw">Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial</title>
				<funder>
					<orgName type="full">Janssen</orgName>
				</funder>
				<funder>
					<orgName type="full">Roche</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004337</idno>
				</funder>
				<funder ref="#_mAZ6xYP">
					<orgName type="full">Chinese PLA Healthcare Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">Daiichi-Sankyo</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100002973</idno>
				</funder>
				<funder>
					<orgName type="full">BMS/ Pfizer</orgName>
				</funder>
				<funder ref="#_pNhNT3S">
					<orgName type="full">National Natural Science Foundation of China</orgName>
					<orgName type="abbreviated">NSFC</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100001809</idno>
				</funder>
				<funder>
					<orgName type="full">Boehringer Ingelheim</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100008349</idno>
				</funder>
				<funder>
					<orgName type="full">Medtronic</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004374</idno>
				</funder>
				<funder>
					<orgName type="full">BMS/Pfizer</orgName>
				</funder>
				<funder>
					<orgName type="full">Microlife</orgName>
				</funder>
				<funder ref="#_NuaJBMs #_HS8B4fw">
					<orgName type="full">Beijing Natural Science Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">Biotronik</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100005035</idno>
				</funder>
				<funder>
					<orgName type="full">Bayer</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004326</idno>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Yutao</forename><surname>Guo</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>PhD, Chinese</roleName><forename type="first">Yundai</forename><surname>Chen</surname></persName>
							<email>yundai_chen301@163.com</email>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Deirdre</forename><forename type="middle">A</forename><surname>Lane</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>b</label> Chinese PLA General Hospital , Beijing , China; Institute of Cardiovascular Sciences ,</note>
								<orgName type="department">Institute of Cardiovascular Sciences</orgName>
								<orgName type="institution">Chinese PLA General Hospital</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country>China;</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>c</label> University of Birmingham , Birmingham , United Kingdom; Aalborg Thrombosis Research Unit , Department of Clinical Medicine ,</note>
								<orgName type="department">Department of Clinical Medicine</orgName>
								<orgName type="laboratory">Aalborg Thrombosis Research Unit</orgName>
								<orgName type="institution">University of Birmingham</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<country>United Kingdom;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Lihong</forename><surname>Liu</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>d</label> Aalborg University , Aalborg , Denmark;</note>
								<orgName type="institution">Aalborg University</orgName>
								<address>
									<settlement>Aalborg</settlement>
									<country>Denmark;</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Yutang</forename><surname>Wang</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Gregory</forename><forename type="middle">Y H</forename><surname>Lip</surname></persName>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Meishan City People&apos;s Hospital , Chendgdu , China.</note>
								<orgName type="institution">Meishan City People&apos;s Hospital</orgName>
								<address>
									<settlement>Chendgdu</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">PLA General Hospital , Department of Cardiology , Beijing 100853 , China.</note>
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">PLA General Hospital</orgName>
								<address>
									<postCode>100853</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">University of Birmingham Centre for Cardiovascular Sciences , City Hos- pital , Birmingham , United Kingdom.</note>
								<orgName type="department">Centre for Cardiovascular Sciences</orgName>
								<orgName type="institution">University of Birmingham</orgName>
								<address>
									<addrLine>City Hos- pital</addrLine>
									<settlement>Birmingham</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_mBdaudV">Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">25F72CD2E8E3CDC4B2637C8C9E55A5A1</idno>
					<idno type="DOI">10.1016/j.amjmed.2017.07.003</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T08:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_HfG9SNC">Atrial fibrillation</term>
					<term xml:id="_uVv6WD5">Drug adherence</term>
					<term xml:id="_Zky2h9H">Mobile health</term>
					<term xml:id="_dwUGy8T">Patient education</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_naGdhqy"><p xml:id="_53CM6pW"><s xml:id="_nWKbXcB">BACKGROUND: Mobile Health technology for the management of patients with atrial fibrillation is unknown.</s><s xml:id="_dXeK6dQ">METHODS: The simple mobile AF (mAF) App was designed to incorporate clinical decision-support tools (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age â‰¥75 years, Diabetes Mellitus, Prior Stroke or TIA, Vascular disease, Age 65-74 years, Sex category], HAS-BLED [Hypertension, Abnormal renal/ liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly],</s></p><p xml:id="_exjRJZC"><s xml:id="_ECxbegR">SAMe-TT2R2 [Sex, Age &lt;60 years, Medical history, Treatment, Tobacco use, Race] scores), educational materials, and patient involvement strategies with self-care protocols and structured follow-up.</s><s xml:id="_a6YArvs">Patients with atrial fibrillation were randomized into 2 groups (mAF App vs usual care) in a cluster randomized design pilot study.</s><s xml:id="_rvztA3c">Patients' knowledge, quality of life, drug adherence, and anticoagulation satisfaction were evaluated at baseline, 1 month, and 3 months.</s><s xml:id="_9ryC4Ak">Usability, feasibility, and acceptability of the mAF App were assessed at 1 month.</s><s xml:id="_BtuUbpH">RESULTS: A total of 113 patients were randomized to mAF App intervention (mean age, 67.4 years; 57.5% were male; mean follow-up, 69 days), and 96 patients were randomized to usual care (mean age, 70.9 years; 55.2% were male; mean follow-up, 95 days).</s><s xml:id="_DRmV4JQ">More than 90% of patients reported that the mAF App was easy, user-friendly, helpful, and associated with significant improvements in knowledge compared with the usual care arm (P values for trend &lt;.05).</s><s xml:id="_Uyswrtd">Drug adherence and anticoagulant satisfaction were significantly better with the mAF App versus usual care (all P &lt; .05).</s><s xml:id="_rm6hVpw">Quality of life scores were significantly increased in the mAF App arm versus usual care, with anxiety and depression reduced (all P &lt; .05).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_n9VVpFk">CONCLUSIONS:</head><p xml:id="_6NZRCcv"><s xml:id="_eQufW4H">The pilot mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that the mAF App, integrating clinical decision support,</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="576.0" lry="774.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_uDAE7WV">INTRODUCTION</head><p xml:id="_9PaafaZ"><s xml:id="_DeUePvQ">Atrial fibrillation is the most common cardiac arrhythmia, with a global health burden of approximately 33.5 million individuals with atrial fibrillation worldwide. <ref type="bibr" target="#b0">1</ref></s><s xml:id="_tJYHbBt">The lifetime risk for developing atrial fibrillation is 21% to 23% in women and 17% to 26% in men. <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref></s><s xml:id="_jWJ8Sh4">3]<ref type="bibr" target="#b3">[4]</ref> In the past 5 decades, age-adjusted atrial fibrillation prevalence globally has increased 5-fold <ref type="bibr" target="#b4">5</ref> and is expected to double by 2050. <ref type="bibr" target="#b0">1</ref> Atrial fibrillation-related stroke is devastating, which has been described as an "atrial fibrillation-related stroke tsunami" without proper treatment with oral anticoagulants. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_dr5kQD6">he underuse or inappropriate use of oral anticoagulants is common in the population with atrial fibrillation, particularly so in many Asian countries. <ref type="bibr" target="#b6">7</ref></s><s xml:id="_tFQPp9r">Even in the new era of non-vitamin K antagonist oral anticoagulants, <ref type="bibr" target="#b4">5</ref> many patients remain undertreated. <ref type="bibr" target="#b7">8</ref></s><s xml:id="_mctTAq9">Also, 28% of high-risk patients (defined as a CHA2DS2-VASc [Congestive heart failure, Hypertension, Age â‰¥75 years, Diabetes Mellitus, Prior Stroke or TIA, Vascular disease, Age 65-74 years, Sex category] score â‰¥2) are not anticoagulated, whereas 51% of very lowrisk patients are inappropriately anticoagulated. <ref type="bibr" target="#b8">9</ref></s><s xml:id="_JwkvvBS">onadherence to atrial fibrillation guidelines is common across all risk strata, ranging from 33% to 68% among the high-risk population. <ref type="bibr" target="#b9">10</ref></s><s xml:id="_nG4P5sy">On the other hand, patients' preferences are another important reason for nonadherence to therapy. <ref type="bibr" target="#b10">11</ref></s><s xml:id="_z9TW52c">Thus, efforts to streamline decision-making for stroke prevention in patients with atrial fibrillation and to improve patients' knowledge are important in the era of non-vitamin K antagonist oral anticoagulants. <ref type="bibr" target="#b11">12</ref></s><s xml:id="_UjQZHje">ovel strategies that incorporate eHealth or Mobile Health encompass the use of information and communication technologies in the management of disease, providing innovative solutions to the problem of long-term management after discharge. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref></s><s xml:id="_zMAjgmx">However, there are limited data on the implementation of Mobile Health technology for the management of patients with atrial fibrillation, particularly in relation to its feasibility, efficacy, and safety.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vPGmt9g">MATERIALS AND METHODS</head><p xml:id="_KpBBqwb"><s xml:id="_ybAu792">A user-friendly mAF</s></p><p xml:id="_7gzytwf"><s xml:id="_bR3TXVu">App was developed for smart phones based on the Android Operating System (Google Inc., Mountain View, Calif) and Apple iOS (Cupertino, Calif), which incorporated clinical decision support (clinical risk scores, ie, CHA2DS2-VASc, HAS-BLED [Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly], and SAMe-TT2R2 [Sex, Age &lt; 60 years, Medical history, Treatment, Tobacco use, Race] score), patient educational programs, patient involvement self-care components, and structured follow-up components.</s></p><p xml:id="_74uD65p"><s xml:id="_bz8jdym">Patients with atrial fibrillation were randomized to 2 groups (mAF App vs usual care) in a cluster randomized design based in 2 hospitals, Chinese PLA General Hospital and Meishan City People's Hospital, between January 1, 2017, and May 1, 2017.</s><s xml:id="_N9cRxFe">Inclusion criteria included adult patients aged &gt;18 years with atrial fibrillation diagnosed with electrocardiogram and 24-hour Holter.</s><s xml:id="_G7DnsFQ">We excluded individuals aged &lt;18 years, those with valvular atrial fibrillation (eg, prosthetic), and those unable to provide written informed consent (Supplementary Figure <ref type="figure" target="#fig_2">1</ref>, available online).</s></p><p xml:id="_yZVDd3w"><s xml:id="_xRTK3HN">Patients' knowledge, quality of life, drug adherence, and anticoagulation satisfaction were evaluated at baseline, 1 month, and 3 months.</s><s xml:id="_QAVQ7Vj">Usability, feasibility, and acceptability of the mAF App were assessed at 1 month.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_caNr6fG">Design of mAF App</head><p xml:id="_vFrK3NH"><s xml:id="_hp99H6e">The mAF App was designed with versions for patients and doctors respectively.</s><s xml:id="_4NEGu9J">The mAF App incorporates details such</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PHpZNtw">CLINICAL SIGNIFICANCE</head><p xml:id="_hGphUTK"><s xml:id="_ezRj6FF">â€¢ Mobile Health technology is increasingly proposed for cardiovascular disease management.</s></p><p xml:id="_3Ms3RUP"><s xml:id="_gEzQbvE">â€¢ The feasibility, efficacy, and safety of Mobile Health technology for the management of patients with atrial fibrillation are unknown.</s></p><p xml:id="_bqUwabY"><s xml:id="_vgPMDPG">â€¢ The pilot mAFA Trial demonstrated that an approach integrating clinical decision support, education, and patientinvolvement strategies using the mAF App would translate to significantly improved knowledge, drug adherence, anticoagulant satisfaction, and quality of life.</s></p><p xml:id="_fFyp2qR"><s xml:id="_3Mxj6K8">as the Personal Health Record, stroke and bleeding risk assessment (CHA2DS2-VASc and HAS-BLED scores, respectively), and a clinical score to aid warfarin control prediction (SAMe-TT2R2), patient educational programs, patient involvement self-care items, and structured follow-up components.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mVrgMnu">Personal Health</head><p xml:id="_p3zDXjT"><s xml:id="_VWBat9U">Record.</s><s xml:id="_Zn5ksyH">The mAF App could record atrial fibrillation features, patient medical history, laboratory tests, atrial fibrillation treatments, antithrombotic drugs, and other pharmacologic treatments at baseline.</s><s xml:id="_XXZrgms">Patients were recommended to upload their laboratory tests (eg, hemoglobin, platelet count, liver/renal function tests, blood lipids), electrocardiogram, and echocardiogram (if available) at 1 month and 3 months after their initial consultation.</s><s xml:id="_SvfXbQe">Clinical Decision Support.</s><s xml:id="_XAyxJQN">The mAF App automatically calculates CHA2DS2-VASc, HAS-BLED, and SAMe-TT2R2 scores after the patient's Personal Health Record is completed (Supplementary Figure 2, available online).</s></p><p xml:id="_KkdZYUS"><s xml:id="_XWpCgus">Patients with a low stroke risk (CHA2DS2-VASc score 0 in men, 1 in women) were recommended no antithrombotic treatment.</s><s xml:id="_mVXScgd">Patients at moderate stroke risk (1 stroke risk factor) were suggested to consider oral anticoagulants balancing against bleeding risk, and those at high stroke risk (CHA2DS2-VASc â‰¥2) were recommended oral anticoagulants.</s><s xml:id="_hEfGRAg">Patients with HAS-BLED â‰¥3 were flagged for followup, and modifiable bleeding risk factors were proactively addressed.</s><s xml:id="_DeQfj8Y">Because non-vitamin K antagonist oral anticoagulants are "self-pay" drugs and not reimbursed in China, if the patients had a SAMe-TT2R2 score 0 to 2, they were considered to receive warfarin treatment.</s><s xml:id="_GTD3zah">If the SAMe-TT2R2 score was &gt;2, the patients would have additional education/ counseling about warfarin and more regular review/ international normalized ratio checks, or to use a nonvitamin K antagonist oral anticoagulant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QRtu8hg">Patient's Educational</head><p xml:id="_GeaF6Zw"><s xml:id="_Hb8MZdy">Program.</s><s xml:id="_RSwbZS2">There were 8 components of the patient's educational program, with additional patient self-support items.</s><s xml:id="_3jS8TYz">Patients followed the educational program on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage themselves at home (Supplementary Figure <ref type="figure" target="#fig_5">3</ref>, available online).</s><s xml:id="_EQQkFJx">Patients' knowledge and understanding were assessed at baseline, 1 month, and 3 months using a 11-item questionnaire regarding atrial fibrillation. <ref type="bibr" target="#b14">15</ref></s><s xml:id="_ETwCEXe">tient Involvement with Self-Care.</s><s xml:id="_E4RW6VF">The patients were encouraged to monitor their heart rate and blood pressure, and feedback on their treatment using the mAF App (Supplementary Figure <ref type="figure">4</ref>, available online).</s><s xml:id="_jV6AM6C">Their quality of life was assessed using the Euro EQ-5D-Y at baseline, 1 month, and 3 months.</s></p><p xml:id="_sv58ufp"><s xml:id="_JChmVYx">Structured Follow-Up.</s><s xml:id="_hBrTrSn">Structured follow-up was planned at 1, 3, 6, 9, and 12 months after consultation/discharge, and included assessment of drug therapy, thrombotic events, bleeding events, quality of life, oral anticoagulant satisfaction, and mAF App investigations (Supplementary Figure <ref type="figure">5</ref>, available online).</s><s xml:id="_avJVxuT">A reminder "alert" was sent automatically to patients 1 week before and after the follow-up time-point by the mAF App.</s></p><p xml:id="_XRFDfuN"><s xml:id="_Gjkvr7a">The patients' drug adherence was assessed at baseline, 1 month, and 3 months with the Pharmacy Quality Alliance adherence measure, with a 3-item Adherence Estimator. <ref type="bibr" target="#b15">16</ref></s><s xml:id="_eArm46M">The Anti-Clot Treatment Scale was adapted to evaluate the satisfaction of patients with oral anticoagulants in this Chinese population with atrial fibrillation (Supplementary Table <ref type="table" target="#tab_3">1</ref>, available online).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XnWws7Q">Data Management, Quality Control, Data Security, and Ethics</head><p xml:id="_HYQMrDx"><s xml:id="_8DZT5mT">Users had a user-sensitive password for access to their mAF App.</s><s xml:id="_CxxrHcg">Personal Health Records were stored as structured data on a cloud platform.</s><s xml:id="_gXQ3S9Z">For example, the medical records and laboratory tests could be uploaded to mAF App as image files, and then the image files were transferred into structured data with optical character recognition technology.</s><s xml:id="_j4VNXqD">Two persons independently double checked the structured data and the source documentation (ie, the image files of laboratory tests and medical records) for consistency and accuracy to achieve good-quality control of data management.</s></p><p xml:id="_SzqmXYr"><s xml:id="_9uzsFEx">Health Insurance Portability and Accountability Act requirements were adopted to confirm data security during data transfer and data storage, in terms of the Administrative Procedures, Physical Safeguards, Technical Security Services, and Technical Security Mechanisms.</s><s xml:id="_EvzCMc5">Data input into analysis was performed by 2 individuals, who were blinded for the intervention groups.</s><s xml:id="_QaZG9Hg">Data were double checked independently by a third investigator.</s><s xml:id="_k482ftH">Patient records and information were anonymized and de-identified before analysis.</s></p><p xml:id="_JZg8AX2"><s xml:id="_cmCqNuN">The Medical Ethics Committee of PLA General Hospital and the China Food and Drug Administration (Registry Number: XZF20120145) approved the present study protocol (Approval Number: S2016-086-01).</s><s xml:id="_TsBPbzg">The present study was registered in the Chinese Clinical Trial Registry, International Clinical Trials Registry Platform of the World Health Organization (ChiCTR-IOR-17010436).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_kQpNv3s">Statistical Analysis</head><p xml:id="_6QWYMcc"><s xml:id="_yEPrj4M">Continuous variables were tested for normality by the Kolmogorov-Smirnov test.</s><s xml:id="_Z7cyvW5">Data with a normal distribution are presented as a mean (standard deviation) and analyzed using the t test.</s><s xml:id="_dvQdEWU">Data with a non-normal distribution are presented as median (interquartile range).</s><s xml:id="_nVU6HVP">The comparison of discrete variables was performed using the chi-square test.</s></p><p xml:id="_Tf5QARN"><s xml:id="_y4GnUWC">The usability, feasibility, and acceptability of the mAF App were investigated at 1 month, and the satisfaction rate was calculated.</s><s xml:id="_e3cUHqj">Data on patients' knowledge, quality of life scores, antithrombotic drugs, and other drugs at the 3 time-points (baseline, 1 month, and 3 months) were presented graphically to illustrate the change in these variables over time between the mAF App and usual care groups.</s><s xml:id="_ag8WMh6">Trends of improvement of patients' knowledge at baseline, 1 month, and 3 months were analyzed with Cochran's and Mantel-Haenszel statistics.</s></p><p xml:id="_qWaQM89"><s xml:id="_KE8yYAD">Patients' adherence to drug therapy was calculated using the 3-item Adherence Estimator scores, comparing patients with usual care and mAF App, and was analyzed with the Mann-Whitney U test.</s></p><p xml:id="_x3BbkDN"><s xml:id="_Teevs8w">Comparative analysis of Anti-Coagulation Satisfaction and Quality of Life questionnaire scores (EuroQol, EQ-5D-Y) between patients with usual care and the mAF App was performed using t tests, and the chi-square test was used for comparisons of improvement of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression at baseline, 1 month, and 3 months.</s></p><p xml:id="_cp5RXsU"><s xml:id="_YzWDgHx">A sample size of 112 patients (56 in each group) allows for a 20% attrition rate in the completion of the questionnaires and would have at least 80% power to detect an 18.5% increase in knowledge about the condition between baseline and follow-up. <ref type="bibr" target="#b16">17</ref></s><s xml:id="_DNCfeng">A beta = 0.20 and alpha = 0.05 were assumed.</s></p><p xml:id="_mwhtQ2K"><s xml:id="_V7w2Zxn">A P value &lt;.05 was considered statistically significant.</s><s xml:id="_aSz3GVu">The 95% confidence intervals were calculated on the basis of Poisson distribution.</s><s xml:id="_hUTS9aF">Statistical analysis was performed using IBM SPSS Statistics version 21.0 (SPSS, Inc, Chicago, Ill).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vgmqF26">RESULTS</head><p xml:id="_cP8kHww"><s xml:id="_CNWVsWy">In a cluster randomization design, 113 patients were randomized to mAF App intervention (mean age, 67.4 years; 57.5% were male) with a mean follow-up of 69 days, whereas 96 patients were randomized to usual care (mean age, 70.9 years; 55.2% were male) with a mean follow-up of 95 days.</s><s xml:id="_KU9U6WK">Of the original cohort, 113 patients with the mAF App had a 1-month follow-up and 71 patients finished the 3-month follow-up; 96 patients with usual care had 1-month and 3-month follow-up visits.</s></p><p xml:id="_4WPBKhu"><s xml:id="_zJNz82Q">Hypertension, coronary artery disease, diabetes, and heart failure were the most common comorbidities in both groups (Table <ref type="table" target="#tab_3">1</ref>).</s><s xml:id="_3ECQZ5j">The patients with the mAF App had more prior atrial fibrillation ablation therapy (P = .036).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KVGqsCs">Usability, Feasibility, Acceptability of the mAF App</head><p xml:id="_ZJfpaRq"><s xml:id="_nxprVAj">More than 90% of patients agreed that the mAF App was easy, user-friendly, and helpful, and they had good feedback with the doctors on the mAF App (Supplementary Figure <ref type="figure">6</ref>, available online).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RuXPq4H">Patients' Knowledge on Atrial Fibrillation</head><p xml:id="_XNGsHMs"><s xml:id="_CqNwyzK">Patients' knowledge was improved greatly in those with the mAF App over time (all P &lt; .05),</s><s xml:id="_2hHgXAm">whereas this was not observed in the patients with usual care (Figure <ref type="figure" target="#fig_2">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HT6NTdP">Quality of Life Improvement in Patients with the mAF App</head><p xml:id="_YWFyzZY"><s xml:id="_PrYJVAy">Quality of life scores were significantly increased in the mAF App arm compared with usual care at baseline and 1 and 3  months (all P &lt; .05)</s><s xml:id="_uhUSQSU">(Figure <ref type="figure" target="#fig_3">2</ref>).</s><s xml:id="_UNFZW62">Self-care improved significantly over time with the mAF App, but not in usual care (all P &lt; .05).</s><s xml:id="_GCnDpkb">Anxiety and depression also tended to be ameliorated for patients using the mAF App compared with usual care over time (all P &lt; .05)</s><s xml:id="_W8Ee6Au">(Table <ref type="table" target="#tab_4">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MnJ7ZPW">Drug Adherence to Therapy</head><p xml:id="_zRtjCfd"><s xml:id="_54Zy3q2">Compared with patients with usual care, drug adherence was significantly better with the mAF App at 1 month and 3 months (all P &lt; .05)</s><s xml:id="_kdZcbUP">(Table <ref type="table" target="#tab_5">3</ref>).</s><s xml:id="_5wkZqM7">Patients with the mAF App were more likely to receive non-vitamin K antagonist oral anticoagulants, ranging from 40.7% to 44.2%, compared with those with usual care (P &lt; .001).</s><s xml:id="_vVRQpmm">There was a slight increase in nonvitamin K antagonist oral anticoagulant use (3.52%) over time in patients using the mAF App (Figure <ref type="figure" target="#fig_5">3</ref>).</s><s xml:id="_DgGYCFd">Secondary prevention of comorbidities for atrial fibrillation was improved in patients with the mAF App compared with patients with usual care (Supplementary Figure <ref type="figure">7</ref>, available online).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_hhwH5YV">Anticoagulation Satisfaction</head><p xml:id="_gVZ9nUR"><s xml:id="_qkRu75X">Patients with usual care expressed more anticoagulant "burden," whereas patients with the mAF App reported more anticoagulant "benefit" (all P &lt; .05)</s><s xml:id="_TmzynHz">(Table <ref type="table" target="#tab_6">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_SBQwyxC">DISCUSSION</head><p xml:id="_9huu966"><s xml:id="_Zwx5NzR">To our knowledge, the mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that the mAF App, integrating clinical decision support, education, and patient-involvement strategies, significantly improved knowledge, drug adherence, quality of life, and anticoagulation satisfaction.</s></p><p xml:id="_2bC3amK"><s xml:id="_JAegUu5">Clinical decision support provided by the mAF App streamlined guideline-based decision-making for stroke prevention in patients with atrial fibrillation and was easily handled by doctors and understood by patients.</s><s xml:id="_JjptCzC">The clinical decision support tools in the mAF App automatically assessed stroke and bleeding risk, and stratified the patients with high-risk stroke/thromboembolism to anticoagulant treatment, while balancing the bleeding risk.</s><s xml:id="_AfNsmYE">Bleeding risk factors were labeled and could be reviewed by doctors and patients.</s><s xml:id="_Zmcph4K">Personalized choice of oral anticoagulants would be advised on the basis of the SAMe-TT2R2 score, resulting in rational decisionmaking on anticoagulant management options.</s></p><p xml:id="_eEEF9k5"><s xml:id="_G4ME3z7">Suboptimal thromboprophylaxis in patients with atrial fibrillation is highly prevalent, contributed to by an inappropriate evaluation of the risks versus benefits of oral anticoagulants, despite various guidelines on atrial fibrillation management. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref></s><s xml:id="_uQDpyqG">Indeed, guideline-adherent antithrombotic management is associated with significantly better outcomes. <ref type="bibr" target="#b19">20</ref></s><s xml:id="_WT2mXku">ne barrier to adherence to guideline-optimized therapy could be the challenges of a "real-world" busy clinical practice, and the clinical decision-making tool in the mAF App could make the process of guideline implementation easier.</s></p><p xml:id="_gHsjPHp"><s xml:id="_AdNB786">To help access to guidelines for the clinician, a pocket guideline App for European guidelines has been developed.</s><s xml:id="_wYUr35W">The CATCH-ME treatment manager is integrated into the atrial fibrillation section, but has yet to be prospectively tested or evaluated. <ref type="bibr" target="#b20">21</ref></s><s xml:id="_UXNu8wQ">Another option is the Atrial Fibrillation Decision Support Tool, which is a patient-specific decision analytic model composed of a 29-state Markov simulation, using information from the Electronic Health Record to integrate patient-specific risk factors for stroke and hemorrhage in its calculations. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_3cYk6DJ">However, the intervention with the Atrial Fibrillation Decision Support Tool did not result in significant improvements in discordant antithrombotic therapy in a population with atrial fibrillation. <ref type="bibr" target="#b22">23</ref></s><s xml:id="_9PTVwTn">Other Apps have been developed to provide stroke and bleeding risk calculations; for example, the Computerised Antithrombotic Risk Assessment Tool Version 2 could calculate the CHADS2 (Congestive heart failure, Hypertension, Age over 75 years, Diabetes Mellitus, Stroke), CHA2DS2-VASc, HAS-BLED, and HEMORR2-HAGES (Hepatic or renal disease, Ethanol abuse, Malignancy, Older age, Reduced platelet count or function, Rebleeding risk, Hypertension, Anemia, Genetic factors, Excessive fall risk, Stroke) scores. <ref type="bibr" target="#b23">24</ref></s><s xml:id="_f2zMFEN">Another clinical decision support tool, which could calculate the CHA2DS2-VASc score and alter the clinician prescription of oral anticoagulants therapy, is being studied. <ref type="bibr" target="#b24">25</ref></s><s xml:id="_dnEaga6">However, these Apps/tools are focused on doctors and not the follow-up and day-to-day management of patients with atrial fibrillation.</s></p><p xml:id="_awWw3R5"><s xml:id="_JvKaGs6">The mAF App not only calculates the clinical risk scores but also automatically makes a follow-up plan, permitting the patient's self-monitoring and timely feedback.</s><s xml:id="_N7J6QBJ">We also show that the mAF App-based self-monitoring and feedback enhanced compliance and adherence to drug therapy and   Clinical follow-up ensures effective and safe anticoagulant therapy in patients with atrial fibrillation.</s><s xml:id="_mmz4ANh">A systematic review of drug adherence, thromboembolism, bleeding events, any adverse effects, renal or hepatic function, and so forth, is recommended for non-vitamin K antagonist oral anticoagulants, <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27</ref> although anticoagulation tests are not needed.</s><s xml:id="_HqMBecM">In one study, approximately two thirds of practitioners adhered to recommendations on clinical and blood test (creatinine and hemoglobin) follow-ups. <ref type="bibr" target="#b27">28</ref></s><s xml:id="_5PefgRV">Clinical risk monitoring is important, particularly for bleeding risk management after discharge/prescription of non-vitamin K antagonist oral anticoagulants, and the mAF App allows a practical tool to monitor the patient's clinical risk profile in "real time" allowing a dynamic assessment (and reassessment) of patient risks and changes over time.</s><s xml:id="_Uq2Pxbx">Moreover, the educational programs provided by the mAF App improved atrial fibrillationrelated knowledge and patient's quality of life.</s><s xml:id="_7SFVRXB">Patient anxiety and depression also were attenuated.</s></p><p xml:id="_Dvjbnaq"><s xml:id="_xmXYnmu">Contemporary atrial fibrillation clinical guidelines advocate incorporation of patient preferences for treatment and support, as well as patient engagement in management decisions. <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b28">29</ref></s><s xml:id="_MUxEG4m">Nonetheless, patient beliefs and misconceptions about their treatment and atrial fibrillation could affect their ability and willingness to adhere to treatment recommendations. <ref type="bibr" target="#b28">29</ref></s><s xml:id="_PwR8ZDF">A prior study  *Compared with the patients with usual care, P &lt; .05.</s><s xml:id="_7TdgC4n">The Anti-Clot Treatment Scale was adapted to evaluate the satisfaction of patients with anticoagulant therapy in this Chinese population with atrial fibrillation.</s><s xml:id="_qTX2wV7">The adapted Anti-Clot Treatment Scale included a 15-item questionnaire, comprising 11 burden items and 4 benefit items.</s><s xml:id="_6gUWFMN">For every question, there are 5 item responses: "1, not at all" was calculated as 1 points; "2, a little" was calculated as 2 points; "3, moderately" was calculated as 3 points; "4, quite a bit" was calculated as 4 points; and "5, extremely" was calculated as 5 points.</s></p><p xml:id="_NhH4FBJ"><s xml:id="_rX6pwfG">has confirmed that a bespoke education intervention significantly improved anticoagulation control of warfarin. <ref type="bibr" target="#b29">30</ref></s><s xml:id="_G5my92N">A higher patient education level has been associated with nonvitamin K antagonist oral anticoagulant selection. <ref type="bibr" target="#b30">31</ref></s><s xml:id="_ft5vdW3">The mAF App provides the specific educational components, in terms of warfarin, non-vitamin K antagonist oral anticoagulants, and specific conditions, that may help patients with self-management.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3VhK5ZQ">Study Limitations</head><p xml:id="_ZHuff5T"><s xml:id="_pnqmzjc">Some limitations of this study need to be addressed.</s><s xml:id="_bEKguTj">This was a clustered randomized study, and a selection bias could exist; however, the distribution of comorbidities between the mAF App and the usual care arms were not significantly different.</s><s xml:id="_DzkRSCN">Moreover, the clinician's preference for oral anticoagulants may have contributed to a higher rate of non-vitamin K antagonist oral anticoagulant use in the mAF App group.</s><s xml:id="_3dWR8dD">The educational program could have made the patients more aware and thus be more likely to receive non-vitamin K antagonist oral anticoagulants.</s><s xml:id="_qmme42d">Finally, the impact on the clinical outcomes (stroke, death, bleeds) of the mAF App needs to be ascertained in a long-term prospective study with clinical outcome data, which was not the principal objective of the present study.</s></p><p xml:id="_4uhJBk3"><s xml:id="_qaPh6TV">Despite these limitations, the present study still shows that the clinical decision support, evidence-based clinical followup, and patients' involvement in self-care can help clinical management for the population with atrial fibrillation, highlighting for the first time an effective Mobile Healthsupport management strategy in such patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_utEHxRa">CONCLUSIONS</head><p xml:id="_gV6MJkZ"><s xml:id="_9HJepK7">The pilot mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that an approach integrating clinical decision support, education, and patient-involvement strategies will translate to significantly improved knowledge, drug adherence, anticoagulant satisfaction, and quality of life.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc><div><p xml:id="_zs6qSdC"><s xml:id="_UsEm9uP">Our aim was to perform a randomized, controlled trial (mAFA; Clinical Trials Registry Number: ChiCTR-IOR-17010436) of a Mobile Health technology-supported atrial fibrillation management model, integrating clinical decision support tools, guideline-based treatment, and patient involvement.</s><s xml:id="_pmV9yFc">The mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>AF</head><figDesc><div><p xml:id="_vrFUspN"><s xml:id="_CBh4hR6">= atrial fibrillation; CAD = coronary artery disease; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age â‰¥75 years, Diabetes Mellitus, Prior Stroke or TIA, Vascular disease, Age 65-74 years, Sex category; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly; LAAO = left atrial appendage occlusion; mAF App = mobile AF App; PAD = peripheral arterial disease; SD = standard deviation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 1</head><label>1</label><figDesc><div><p xml:id="_NwXUbY2"><s xml:id="_cBrsv9B">Figure 1 Patients' knowledge of atrial fibrillation with usual care and mAF App at baseline, 1 month, and 3 months.</s><s xml:id="_gM8yhX5">*P for trend &lt;.05 at baseline, 1 month, and 3 months after discharge.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2</head><label>2</label><figDesc><div><p xml:id="_k2CvWpS"><s xml:id="_XHZTKEg">Figure 2 Time trends for quality of life scores of patients with the mAF App.</s><s xml:id="_aShWSny">*Quality of life questionnaire was cited from the EuroQol.</s><s xml:id="_uWfEWsQ">Compared with patients with usual care, patients with the mAF App, P &lt; .05.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><figDesc><div><p xml:id="_Uc8MGdk"><s xml:id="_qAaRbWZ">anticoagulant satisfaction.</s><s xml:id="_SahnzZt">With the planned follow-up by the mAF App, the clinician receives the patient's updated clinical condition, reevaluates the patient's clinical risk profile (especially because stroke and bleeding risks are not static), and regulates the dosage and use of various drugs.</s><s xml:id="_EnP8Ws9">Meanwhile, patients have their questions clarified, become involved in their self-management, and benefit overall from their treatment plan.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 3</head><label>3</label><figDesc><div><p xml:id="_jdvq65d"><s xml:id="_xAzS27C">Figure 3 Antithrombotic treatment in patients with the mAF App and usual care at baseline, 1 month, and 3 months after discharge.</s><s xml:id="_DrBB55M">A, Usual care.</s><s xml:id="_Fk45jyU">B, mAF App.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="10,36.95,458.48,504.07,249.49" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="11,100.25,48.38,375.90,339.43" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="12,24.71,47.66,522.32,302.71" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="13,161.21,51.86,271.07,405.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 1</head><label>1</label><figDesc><div><p xml:id="_sazHj96"><s xml:id="_H2Ft8Ys">Baseline Characteristics</s></p></div></figDesc><table><row><cell>mAF App</cell><cell>Usual Care</cell><cell></cell></row><row><cell>(n = 113)</cell><cell>(n = 96)</cell><cell>P Value</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2</head><label>2</label><figDesc><div><p xml:id="_a8qn8RX"><s xml:id="_s7gbhBy">Quality of Life Questionnaire Responses in Patients with mAF App and Usual Care*</s></p></div></figDesc><table><row><cell></cell><cell cols="2">On Discharge</cell><cell></cell><cell cols="2">1 Month After Discharge</cell><cell></cell><cell cols="2">3 Months After Discharge</cell><cell></cell></row><row><cell></cell><cell cols="2">mAF App Usual Care</cell><cell>P Value</cell><cell>mAF App</cell><cell>Usual Care</cell><cell>P Value</cell><cell>mAF App</cell><cell>Usual Care</cell><cell>P Value</cell></row><row><cell>Mobility</cell><cell cols="2">(n = 113) (n = 96)</cell><cell></cell><cell>(n = 113)</cell><cell>(n = 96)</cell><cell></cell><cell>(n = 71)</cell><cell>(n = 96)</cell><cell></cell></row><row><cell>No problems</cell><cell>70.80%</cell><cell>26.04%</cell><cell>&lt;.001</cell><cell>76.36%</cell><cell>26.04%</cell><cell>&lt;.001</cell><cell>77.46%</cell><cell>27.08%</cell><cell>&lt;.001</cell></row><row><cell>Slight problems</cell><cell>23.89%</cell><cell>32.29%</cell><cell>.180</cell><cell>15.45%</cell><cell>35.42%</cell><cell>.001</cell><cell>15.49%</cell><cell>36.46%</cell><cell>&lt;.001</cell></row><row><cell>Moderate problems</cell><cell>5.31%</cell><cell>31.25%</cell><cell>&lt;.001</cell><cell>7.27%</cell><cell>31.25%</cell><cell>&lt;.001</cell><cell>5.63%</cell><cell>29.17%</cell><cell>&lt;.001</cell></row><row><cell>Severe problems</cell><cell>-</cell><cell>5.21%</cell><cell>.014</cell><cell>-</cell><cell>2.08%</cell><cell>.123</cell><cell>-</cell><cell>2.08%</cell><cell>.221</cell></row><row><cell>Unable to walk about</cell><cell>-</cell><cell>5.21%</cell><cell>.014</cell><cell>0.91%</cell><cell>5.21%</cell><cell>.062</cell><cell>1.41%</cell><cell>5.21%</cell><cell>.062</cell></row><row><cell>Self-care</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No problems</cell><cell>77.88%</cell><cell>55.21%</cell><cell>&lt;.001</cell><cell>83.64%</cell><cell>65.63%</cell><cell>&lt;.001</cell><cell>87.32%</cell><cell>68.75%</cell><cell>&lt;.001</cell></row><row><cell>Slight problems</cell><cell>18.58%</cell><cell>21.88%</cell><cell>.449</cell><cell>15.45%</cell><cell>15.63%</cell><cell>.908</cell><cell>11.27%</cell><cell>11.46%</cell><cell>.272</cell></row><row><cell>Moderate problems</cell><cell>1.77%</cell><cell>9.38%</cell><cell>&lt;.001</cell><cell>-</cell><cell>8.33%</cell><cell>.002</cell><cell>-</cell><cell>9.38%</cell><cell>.001</cell></row><row><cell>Severe problems</cell><cell>1.77%</cell><cell>4.17%</cell><cell>.301</cell><cell>-</cell><cell>2.08%</cell><cell>.123</cell><cell>-</cell><cell>2.08%</cell><cell>.221</cell></row><row><cell>Unable to wash or dress</cell><cell>-</cell><cell>9.38%</cell><cell>.001</cell><cell>0.91%</cell><cell>8.33%</cell><cell>.008</cell><cell>1.41%</cell><cell>8.33%</cell><cell>.008</cell></row><row><cell>Usual activities</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No problems</cell><cell>69.91%</cell><cell>37.50%</cell><cell>&lt;.001</cell><cell>78.18%</cell><cell>45.83%</cell><cell>&lt;.001</cell><cell>77.46%</cell><cell>53.13%</cell><cell>&lt;.001</cell></row><row><cell>Slight problems</cell><cell>27.43%</cell><cell>30.21%</cell><cell>.659</cell><cell>20.00%</cell><cell>27.08%</cell><cell>.252</cell><cell>19.72%</cell><cell>18.75%</cell><cell>.203</cell></row><row><cell>Moderate problems</cell><cell>2.65%</cell><cell>19.79%</cell><cell>&lt;.001</cell><cell>0.91%</cell><cell>16.67%</cell><cell>&lt;.001</cell><cell>1.41%</cell><cell>16.67%</cell><cell>.001</cell></row><row><cell>Severe problems</cell><cell>-</cell><cell>3.13%</cell><cell>.001</cell><cell>-</cell><cell>2.08%</cell><cell>.123</cell><cell>-</cell><cell>3.13%</cell><cell>.133</cell></row><row><cell>Unable to do usual activities</cell><cell>-</cell><cell>9.38%</cell><cell>.001</cell><cell>0.91%</cell><cell>8.33%</cell><cell>.008</cell><cell>1.41%</cell><cell>8.33%</cell><cell>.050</cell></row><row><cell>Pain/discomfort</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>No pain or discomfort</cell><cell>63.70%</cell><cell>35.42%</cell><cell>&lt;.001</cell><cell>59.09%</cell><cell>41.67%</cell><cell>.016</cell><cell>63.38%</cell><cell>40.63%</cell><cell>.006</cell></row><row><cell>Slight pain or discomfort</cell><cell>25.66%</cell><cell>39.58%</cell><cell>.046</cell><cell>33.64%</cell><cell>41.67%</cell><cell>.231</cell><cell>25.35%</cell><cell>45.83%</cell><cell>.007</cell></row><row><cell>Moderate pain or discomfort</cell><cell>10.62%</cell><cell>20.83%</cell><cell>.041</cell><cell>6.36%</cell><cell>12.50%</cell><cell>.114</cell><cell>9.86%</cell><cell>10.42%</cell><cell>.906</cell></row><row><cell>Severe pain or discomfort</cell><cell>-</cell><cell>1.04%</cell><cell>.277</cell><cell>0.91%</cell><cell>2.08%</cell><cell>.468</cell><cell>1.41%</cell><cell>1.04%</cell><cell>.829</cell></row><row><cell>Extreme pain or discomfort</cell><cell>-</cell><cell>3.13%</cell><cell>.058</cell><cell>-</cell><cell>2.08%</cell><cell>.123</cell><cell>-</cell><cell>2.08%</cell><cell>.221</cell></row><row><cell>Anxiety/depression</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Not anxious or depressed</cell><cell>50.44%</cell><cell>52.08%</cell><cell>.831</cell><cell>62.70%</cell><cell>62.50%</cell><cell>.935</cell><cell>57.75%</cell><cell>61.46%</cell><cell>.629</cell></row><row><cell>Slightly anxious or depressed</cell><cell>40.71%</cell><cell>21.88%</cell><cell>.005</cell><cell>31.82%</cell><cell>19.79%</cell><cell>.048</cell><cell>32.39%</cell><cell>20.83%</cell><cell>.091</cell></row><row><cell cols="2">Moderately anxious or depressed 8.85%</cell><cell>20.83%</cell><cell>.014</cell><cell>5.45%</cell><cell>14.58%</cell><cell>.023</cell><cell>9.86%</cell><cell>14.58%</cell><cell>.363</cell></row><row><cell>Severely anxious or depressed</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>1.04%</cell><cell>.388</cell></row><row><cell cols="2">Extremely anxious or depressed -</cell><cell>5.21%</cell><cell>.013</cell><cell>-</cell><cell>3.13%</cell><cell>.058</cell><cell>-</cell><cell>2.08%</cell><cell>.221</cell></row><row><cell>mAF App = mobile AF App.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">*Quality of Life questionnaire was cited from the EuroQol.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3</head><label>3</label><figDesc><div><p xml:id="_uaZhffU"><s xml:id="_H5fexm3">Drug Adherence at Baseline, 1 Month, and 3 Months* Pharmacy Quality Alliance adherence measures: 3-item Adherence Estimator.</s><s xml:id="_h3HXKRj">Low risk = score of 0, moderate risk = score of 2-7, and high risk = score of 8-36.</s></p></div></figDesc><table><row><cell></cell><cell>mAF App</cell><cell>Usual Care</cell><cell>P Value</cell></row><row><cell>Baseline</cell><cell>n = 113</cell><cell>n = 96</cell></row><row><cell></cell><cell>4 (4-11)</cell><cell>4 (4-11)</cell><cell>.870</cell></row><row><cell>1 mo</cell><cell>n = 113</cell><cell>n = 96</cell></row><row><cell></cell><cell>0 (0-4)</cell><cell>4 (0-11)</cell><cell>&lt;.001</cell></row><row><cell>3 mo</cell><cell>n = 71</cell><cell>n = 96</cell></row><row><cell></cell><cell>2 (0-4)</cell><cell>4 (0-11)</cell><cell>&lt;.001</cell></row></table><note xml:id="_rqu88q9"><p><s xml:id="_fuWrkJc">mAF App = mobile AF App.</s><s xml:id="_KBj2juF">*</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 4</head><label>4</label><figDesc><div><p xml:id="_cnHrQmG"><s xml:id="_4mymqUa">Anticoagulation Satisfaction in Patients with mAF App and Usual Care*</s></p></div></figDesc><table><row><cell></cell><cell>Usual Care (n = 46)</cell><cell></cell><cell>mAF App (n = 65)</cell><cell></cell><cell>P Value</cell></row><row><cell>Baseline</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Burden Scale, mean (SD)</cell><cell>20.83</cell><cell>(6.61)</cell><cell>17.58</cell><cell>(8.10)</cell><cell>.028</cell></row><row><cell>Benefit Scale, mean (SD)</cell><cell>13.31</cell><cell>(3.39)</cell><cell>14.11</cell><cell>(3.65)</cell><cell>.256</cell></row><row><cell>1 mo</cell><cell>Usual care (n = 44)</cell><cell></cell><cell>mAF App (n = 63)</cell><cell></cell><cell>P</cell></row><row><cell>Burden Scale, mean (SD)</cell><cell>19.40</cell><cell>(6.05)</cell><cell>16.04</cell><cell>(7.50)</cell><cell>.018</cell></row><row><cell>Benefit Scale, mean (SD)</cell><cell>14.19</cell><cell>(3.18)</cell><cell>15.09</cell><cell>(2.38)</cell><cell>.013</cell></row><row><cell>3 mo</cell><cell>Usual care (n = 45)</cell><cell></cell><cell>mAF App (n = 42)</cell><cell></cell><cell>P</cell></row><row><cell>Burden Scale, mean (SD)</cell><cell>19.30</cell><cell>(6.39)</cell><cell>15.57</cell><cell>(6.57)</cell><cell>.008</cell></row><row><cell>Benefit Scale, mean (SD)</cell><cell>14.21</cell><cell>(3.37)</cell><cell>15.60</cell><cell>(2.73)</cell><cell>.052</cell></row></table><note xml:id="_Hwr5rRD"><p><s xml:id="_y2VUQTT">mAF App = mobile AF App; SD = standard deviation.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_5PKDmWV"><s xml:id="_xfAYPrn">The American Journal of Medicine, Vol 130,No 12, December 2017</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_Fmhv9ZY">ACKNOWLEDGMENTS</head><p xml:id="_Uzc6XgT"><s xml:id="_xkHVy4F">The authors thank <rs type="person">Rujuan Liao</rs>, <rs type="affiliation">Chinese PLA General Hospital</rs>, who oversaw the data input and quality checks, and <rs type="person">Xiaoyu Tang</rs>, for the recruitment of participants.</s></p></div>
			</div>
			<div type="funding">
<div xml:id="_rjswne9"><p xml:id="_zCVTmFf"><s xml:id="_jqrMzWj">This research project was funded by <rs type="funder">Chinese PLA Healthcare Foundation</rs> (<rs type="grantNumber">13BJZ40</rs>), <rs type="funder">Beijing Natural Science Foundation</rs> (<rs type="grantNumber">7142149</rs>), <rs type="funder">Beijing Natural Science Foundation</rs> (<rs type="grantNumber">Z141100002114050</rs>), and <rs type="funder">National Natural Science Foundation of China</rs> (<rs type="grantNumber">H2501</rs>).</s></p><p xml:id="_pfAMEvE"><s xml:id="_ax4W8AB">Conflicts of Interest: GYHL: Consultant for <rs type="institution">Bayer</rs>/<rs type="funder">Janssen</rs>, <rs type="funder">BMS/ Pfizer</rs>, <rs type="funder">Biotronik</rs>, <rs type="funder">Medtronic</rs>, <rs type="funder">Boehringer Ingelheim</rs>, <rs type="funder">Microlife</rs>, and <rs type="funder">Daiichi-Sankyo</rs>.</s><s xml:id="_4sUz55s">Speaker for <rs type="funder">Bayer</rs>, <rs type="funder">BMS/Pfizer</rs>, <rs type="funder">Medtronic</rs>, <rs type="funder">Boehringer Ingelheim</rs>, <rs type="funder">Microlife</rs>, <rs type="funder">Roche</rs>, and <rs type="funder">Daiichi-Sankyo</rs>.</s><s xml:id="_7TdUVnF">No fees are received personally.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_mAZ6xYP">
					<idno type="grant-number">13BJZ40</idno>
				</org>
				<org type="funding" xml:id="_NuaJBMs">
					<idno type="grant-number">7142149</idno>
				</org>
				<org type="funding" xml:id="_HS8B4fw">
					<idno type="grant-number">Z141100002114050</idno>
				</org>
				<org type="funding" xml:id="_pNhNT3S">
					<idno type="grant-number">H2501</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MA2eKVn">SUPPLEMENTARY DATA</head><p xml:id="_ecqgAQR"><s xml:id="_AQvCEZs">Supplementary Material accompanying this article can be found in the online version at doi: 10.1016/j.amjmed</s><s xml:id="_mSs77wr">.2017.07.003.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_P8frNKQ">APPENDIX</head><p xml:id="_VnAUA6h"><s xml:id="_6Fb6A2t">Supplementary Figure <ref type="figure">1</ref> Flow chart.</s></p><p xml:id="_stDwMsm"><s xml:id="_jjCv5Wv">Supplementary Figure <ref type="figure">2</ref> Clinical decision support.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xhHd74U">1396.e1 Guo et al mAF App Randomized Trial</head><p xml:id="_Y5yapVK"><s xml:id="_P5j3AbE">Supplementary Figure <ref type="figure">3</ref> Patients' educational program.</s><s xml:id="_baJAucJ">*Patients followed the educational program on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage themselves at home.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GyjWUD2">1396.e2</head><p xml:id="_6Ygrym5"><s xml:id="_R3ugS6V">The American Journal of Medicine, Vol 130, No 12, December 2017</s></p><p xml:id="_sJSEFtP"><s xml:id="_qhz2dMS">Supplementary Figure <ref type="figure">4</ref> Patients' involvement in self-care.</s><s xml:id="_Uwxc2HE">*Patients could monitor their blood pressure and pulse rate, and be involved in their management.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7c7yxp3">1396.e3 Guo et al mAF App Randomized Trial</head><p xml:id="_V59nUMZ"><s xml:id="_jGtJVjX">Supplementary Figure <ref type="figure">5</ref> Structured follow-up in patients with the mAF App.</s><s xml:id="_Vzd33tY">*The structured follow-up was planned at 1, 3, 6, 9, and 12 months after consultation/discharge, and included drug therapy, thrombotic events, bleeding events, quality of life, anticoagulant satisfaction, and mAF App investigation.</s><s xml:id="_nURMtBB">A reminder alert was sent automatically to patients 1 week before and after the follow-up time-point by the mAF App.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xbMwBRP">1396.e4</head><p xml:id="_naYgWbJ"><s xml:id="_bd4pjwT">The American Journal of Medicine, Vol 130, No</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_49WayeX">Total (scores)</head><p xml:id="_nBxBh3x"><s xml:id="_d9jXHw4">*"1, Not at all" was calculated as 1 points.</s><s xml:id="_dVU7gsF">"2, A little" was calculated as 2 points, "3, Moderately" was calculated as 3 points.</s><s xml:id="_9QrpwjU">"4, Quite a bit" was calculated as 4 points.</s><s xml:id="_3HsRgEY">"5, Extremely" was calculated as 5 points.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bQRNXP3">1396.e6</head><p xml:id="_gDJX9eV"><s xml:id="_PBESYM7">The American Journal of Medicine, Vol 130, No 12, December 2017</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_bdvF6sJ">Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Havmoeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Narayanan</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.113.005119</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VhGTgYN">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="837" to="847" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiol- ogy of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_DGFh2MF">Lifetime risk for development of atrial fibrillation: the Framingham Heart Study</title>
		<author>
			<persName><forename type="first">Lloyd-Jones Dm</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Leip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_afA449E">Circulation</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1042" to="1046" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for develop- ment of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-1046.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_zx37NCG">Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Heeringa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Van Der Kuip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hofman</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehi825</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yPFvJ34">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="949" to="953" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-953.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_Jka4RmU">Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1378/chest.14-0321</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RPzXFUe">Chest</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="109" to="119" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guo Y, Tian Y, Wang H, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147:109-119.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_ky42xua">50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Schnabel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gona</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(14)61774-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GWsve69">Lancet</title>
		<imprint>
			<biblScope unit="volume">386</biblScope>
			<biblScope unit="page" from="154" to="162" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154-162.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_FAjJmwr">Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Cerasuolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Montero-Odasso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>IbaÃ±ez</surname></persName>
		</author>
		<idno type="DOI">10.1177/1747493016687579</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8ZReKxb">Int J Stroke</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="222" to="228" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cerasuolo JO, Montero-Odasso M, IbaÃ±ez A, et al. Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami. Int J Stroke. 2017;12:222-228.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_5mFVfua">Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tdf7NGK">Chest</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="62" to="72" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guo Y, Wang H, Tian Y, et al. Time trends of aspirin and warfarin use on stroke and bleeding events in Chinese patients with new-onset atrial fibrillation. Chest. 2015;148:62-72.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_vmK9bkE">The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Huisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paquette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_R5zhfVc">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="777" to="785" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huisman MV, Rothman KJ, Paquette M, et al. The changing land- scape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol. 2017;69:777-785.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_Gvqbxrk">Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Camm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Accetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ambrosio</surname></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2016-309832</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GwJnHSS">Heart</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="307" to="314" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treat- ment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103:307-314.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_sjrm8M3">Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey</title>
		<author>
			<persName><forename type="first">H</forename><surname>Gamra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Murin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-E</forename><surname>Chiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hQ8m6Rs">Arch Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="77" to="87" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gamra H, Murin J, Chiang C-E, et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis. 2014;107:77- 87.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_KjqzhPt">Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on nonvitamin K antagonist oral anticoagulants</title>
		<author>
			<persName><forename type="first">V</forename><surname>Raparelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Proietti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cangemi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zwWDw7A">Thromb Haemost</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="209" to="218" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral antico- agulant therapy in patients with atrial fibrillation. Focus on non- vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209- 218.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_3ZD8tvf">Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making</title>
		<author>
			<persName><forename type="first">G</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gyh</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Freedman</surname></persName>
		</author>
		<idno type="DOI">10.1160/th16-11-0876</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4HQ9Bp2">Thromb Haemost</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="1230" to="1239" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lip G, Lip GYH, Freedman B, et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117:1230- 1239.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_rzxYYaK">Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific statement from the American Heart Association</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Azar</surname></persName>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000232</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wdETPYA">Circulation</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="1157" to="1213" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burke LE, Ma J, Azar KM, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scientific state- ment from the American Heart Association. Circulation. 2015;132:1157- 1213.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_sQ6K4Uy">e-Health: a position statement of the European Society of Cardiology</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Cowie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bax</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bruining</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehv416</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wQrkFdy">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="63" to="66" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cowie MR, Bax J, Bruining N, et al. e-Health: a position statement of the European Society of Cardiology. Eur Heart J. 2016;37:63- 66.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_wdfb8W6">The atrial fibrillation knowledge scale: development, validation and results</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hendriks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Crijns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Tieleman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijcard.2012.12.047</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_e7YVsyA">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="1422" to="1428" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hendriks JM, Crijns HJ, Tieleman RG, et al. The atrial fibrillation knowl- edge scale: development, validation and results. Int J Cardiol. 2013;168:1422-1428.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_5rg7ne4">The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Mchorney</surname></persName>
		</author>
		<idno type="DOI">10.1185/03007990802619425</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qJvyQcz">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="215" to="238" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McHorney CA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin. 2009;25:215-238.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_RxgKwvx">The value of education and selfmonitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">I</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kamali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kesteven</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2141.2004.05074.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j2qmbd7">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="557" to="564" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khan TI, Kamali F, Kesteven P, et al. The value of education and self- monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126:557- 564.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_yzDeNYH">focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Camm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Caterina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kahZHZb">Europace</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1385" to="1413" />
			<date type="published" when="2012">2012. 2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. De- veloped with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_AQU2jUc">AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>January</surname></persName>
			<affiliation>
				<orgName type="collaboration">AHA Task Force Members</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Wann</surname></persName>
			<affiliation>
				<orgName type="collaboration">AHA Task Force Members</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Alpert</surname></persName>
			<affiliation>
				<orgName type="collaboration">AHA Task Force Members</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Acc</forename></persName>
			<affiliation>
				<orgName type="collaboration">AHA Task Force Members</orgName>
			</affiliation>
		</author>
		<idno type="DOI">10.1161/cir.0000000000000719</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BRh6FZ6">Circulation</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="2071" to="2104" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">January CT, Wann LS, Alpert JS, ACC/AHA Task Force Members, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guide- lines and the Heart Rhythm Society. Circulation. 2014;130:2071- 2104.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_zSM6NAT">Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Laroche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Popescu</surname></persName>
		</author>
		<idno type="DOI">10.1093/europace/euv269</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8eAX2hJ">Europace</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1777" to="1786" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lip GY, Laroche C, Popescu MI, et al. Improved outcomes with Eu- ropean Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP- AF General Pilot Registry. Europace. 2015;17:1777-1786.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_qAEU4sw">ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kirchhof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Benussi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kotecha</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehx039</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hMnYvAK">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2893" to="2962" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_8k4KFkV">Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Eckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Wise</surname></persName>
		</author>
		<idno type="DOI">10.1111/jgs.14099</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xuK8wZs">J Am Geriatr Soc</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1054" to="1060" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eckman MH, Lip GY, Wise RE, et al. Using an atrial fibrillation de- cision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc. 2016;64:1054-1060.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_4z99uSF">Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Eckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Wise</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2016.02.009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5yfrDT8">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="17" to="27" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eckman MH, Lip GY, Wise RE, et al. Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation. Am Heart J. 2016;176:17-27.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_SzznStX">Pilot of a computerised antithrombotic risk assessment tool version 2 (CARATV2.0) for stroke prevention in atrial fibrillation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bajorek</surname></persName>
		</author>
		<idno type="DOI">10.5603/cj.a2017.0003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BH9TYbR">Cardiol J</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="176" to="187" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang Y, Bajorek B. Pilot of a computerised antithrombotic risk as- sessment tool version 2 (CARATV2.0) for stroke prevention in atrial fibrillation. Cardiol J. 2017;24:176-187.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_bjY5crn">Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): rationale and design of a cluster randomized trial in the primary care setting</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">O</forename><surname>Karlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nilsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Charitakis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2017.02.009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9dRVUE3">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="45" to="52" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Karlsson LO, Nilsson S, Charitakis E, et al. Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): rationale and design of a cluster randomized trial in the primary care setting. Am Heart J. 2017;187:45-52.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_Kz9qEET">Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Heidbuchel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Verhamme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alings</surname></persName>
		</author>
		<idno type="DOI">10.1093/europace/euv309</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_75j5HdQ">Europace</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1467" to="1507" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K an- tagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467-1507.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_A64ctp2">Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice-a survey of Swiss general internal medicine practitioners</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Sauter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Melis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Hautz</surname></persName>
		</author>
		<idno type="DOI">10.1186/s40064-016-3722-z</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Vgg3wTd">Springerplus</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">2030</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sauter TC, Melis C, Hautz WE, et al. Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice-a survey of Swiss general internal medicine practitioners. Springerplus. 2016;5:2030.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_qbYTByW">Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n CardÃ­aca y ElectrofisiologÃ­a (SOLEACE)</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Aguinaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>BlomstrÃ¶m-Lundqvist</surname></persName>
		</author>
		<idno type="DOI">10.1093/europace/eux339</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gGuy8wU">Europace</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1747" to="1769" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lane DA, Aguinaga L, BlomstrÃ¶m-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their manage- ment: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de EstimulaciÃ³n CardÃ­aca y ElectrofisiologÃ­a (SOLEACE). Europace. 2015;17:1747-1769.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_eHQAeDF">Patients&apos; experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: a qualitative study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Clarkesmith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gyh</forename><surname>Lip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lane</forename><surname>Da</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.thromres.2017.03.002</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ekuGVRE">Thromb Res</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clarkesmith DE, Lip GYH, Lane DA. Patients&apos; experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: a qualitative study. Thromb Res. 2017;153:19- 27.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_cdCDzjS">Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Clarkesmith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Pattison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">Y</forename><surname>Lip</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0074037</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WR72ffP">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e74037</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clarkesmith DE, Pattison HM, Lip GY, et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One. 2013;8:e74037.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_ZJdb9NZ">Factors associated with nonvitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Steinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Shrader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thomas</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2017.03.024</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9TVGqu4">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="40" to="47" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Steinberg BA, Shrader P, Thomas L, et al. Factors associated with non- vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2017;189:40-47.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
